Amyotrophic lateral sclerosis is a nervous system disorder that progressively degenerates muscles and affects the functioning of the physical body. The disease is also acknowledged as motor neuron or Lou Gehrig’s disease. ALS occurs mainly in the 40-60 age groups and can sometimes develop at a young age also due to the inheritance of genetic mutations. The disease causes damage to nerve cells, brain and spinal cord, which affects breathing, swallowing, speech and mobility. ALS disease is of two types depending upon its cause, namely sporadic and familial. The main cause of ALS disease is chemical imbalance with higher levels of glutamate in body, disorganized immune response, mishandling of proteins and few of the risk factors such as vigorous physical activity, exposure to viral agents, and trauma. There is currently no cure for ALS, but medications, advanced stem cell therapy, and some physiotherapy treatments can relieve symptoms of the disease.
Early symptoms of ALS include muscle twitches in the leg, shoulder, arm or tongue, Tight & stiff muscles (spasticity), muscle cramps, Slurred & nasal speech, muscle weakness affecting an arm, neck, leg or diaphragm and difficulty chewing or swallowing. As the disease progresses, the muscle weakness & atrophy spread to the other parts of body. Patients may develop issues with moving, speaking or forming words (dysarthria), swallowing (called dysphagia), and breathing (dyspnea). Although the sequence of symptoms and the speed at which the disease progresses can vary from person to person, eventually people are unable to stand or walk, lie down or stand up, or use their hands and arms on their own.
As per analysis, “Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” major organizations active in the Europe ALS market including Biogen Inc., F.Hoffmann-La Roche AG, Amylyx Pharmaceuticals Inc., Corestem, Inc., Biohaven Pharmaceutical Holding Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., and among others. Key players are pursuing various growth strategies for instance partnerships & collaborations, product launches, mergers & acquisitions, and are contributing to the growth of the Amyotrophic Lateral Sclerosis (ALS) market worldwide.
Factors such as rise in awareness about its treatment, increase in prevalence of amyotrophic lateral sclerosis (ALS) disease and growth in demand for personalized treatment drugs along with rising geriatric populations are driving the growth of the Europe amyotrophic lateral sclerosis treatment market. ALS is more common in developed countries because sedentary lifestyles increase the risk of geriatric disease, creating a need for new therapies and special medicines for ALS. Apart from this, threat of patent expiration may impact the market.
It is projected that Europe Amyotrophic Lateral Sclerosis (ALS) Treatment market will be reached at rapid pace on account of rise in research & development (R&D) for treatment of ALS and increase in prevalence of ALS during the forecast period.
For More Information, click on the link below:-
Europe Amyotrophic Lateral Sclerosis Treatment Market Research Report
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
